Bio News
Pays Arrowhead $25 million upfront Aims to develop combination therapy with existing treatment Rezdiffra
Madrigal has licensed a MASH drug candidate from Arrowhead for a total of $1 billion (approximately 1.45 trillion won). The RNAi therapy reduced liver fat by 46% after a single dose in patients with a specific genetic variant in a phase 1 trial. Madrigal plans to seek synergy with its existing treatment, Rezdiffra, targeting these patients, who account for 30% of those with MASH.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
